Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the fourteen ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12-month price […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities researchers at Leerink Partnrs issued their Q3 2023 earnings per share estimates for shares of Cytokinetics in a research report issued on Tuesday, August 15th. Leerink Partnrs analyst R. Ruiz anticipates that the biopharmaceutical company will post earnings per share of ($0.80) for the quarter. Leerink Partnrs […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) – Equities research analysts at Leerink Partnrs issued their Q3 2023 earnings per share estimates for shares of Cytokinetics in a research note issued to investors on Tuesday, August 15th. Leerink Partnrs analyst R. Ruiz expects that the biopharmaceutical company will post earnings per share of ($0.80) for the […]
Leerink Partnrs reissued their outperform rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, PriceTargets.com reports. Leerink Partnrs also issued estimates for Cytokinetics’ FY2023 earnings at ($4.32) EPS, FY2024 earnings at ($3.95) EPS, FY2025 earnings at ($2.85) EPS and FY2026 earnings at ($0.35) EPS. Several other analysts […]
Tekla Capital Management LLC grew its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 191.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 219,025 shares of the biopharmaceutical company’s stock after buying an additional 143,886 shares during the quarter. Tekla […]